CRENESSITY Trademark

Trademark Overview

On Wednesday, September 15, 2021, a trademark application was filed for CRENESSITY with the United States Patent and Trademark Office. The USPTO has given the CRENESSITY trademark a serial number of 97028747. The federal status of this trademark filing is REGISTERED as of Tuesday, May 27, 2025. This trademark is owned by Neurocrine Biosciences, Inc.. The CRENESSITY trademark is filed in the Pharmaceutical Products category with the following description:

pharmaceutical preparations for the treatment of hormonal, genetic and endocrine disorders and conditions; pharmaceuticals for human use for the treatment of rare and orphan diseases, disorders and conditions; pharmaceutical preparations for the treatment of congenital adrenal hyperplasia
crenessity

General Information

Serial Number97028747
Word MarkCRENESSITY
Filing DateWednesday, September 15, 2021
Status700 - REGISTERED
Status DateTuesday, May 27, 2025
Registration Number7811758
Registration DateTuesday, May 27, 2025
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 6, 2022

Trademark Statements

Goods and Servicespharmaceutical preparations for the treatment of hormonal, genetic and endocrine disorders and conditions; pharmaceuticals for human use for the treatment of rare and orphan diseases, disorders and conditions; pharmaceutical preparations for the treatment of congenital adrenal hyperplasia

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, October 21, 2021
Primary Code005
First Use Anywhere DateSaturday, December 21, 2024
First Use In Commerce DateSaturday, December 21, 2024

Trademark Owner History

Party NameNeurocrine Biosciences, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92130
Party NameNeurocrine Biosciences, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92130
Party NameNeurocrine Biosciences, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92130

Trademark Events

Event DateEvent Description
Saturday, September 18, 2021NEW APPLICATION ENTERED
Thursday, October 21, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, May 6, 2022PRIORITY ACTION WRITTEN
Wednesday, November 2, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, May 3, 2022ASSIGNED TO EXAMINER
Friday, May 6, 2022PRIORITY ACTION E-MAILED
Friday, May 6, 2022NOTIFICATION OF PRIORITY ACTION E-MAILED
Wednesday, November 2, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, November 2, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, November 3, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, November 16, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, December 6, 2022PUBLISHED FOR OPPOSITION
Tuesday, December 6, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 31, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, July 26, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, July 26, 2023SOU EXTENSION 1 FILED
Wednesday, July 26, 2023SOU EXTENSION 1 GRANTED
Friday, July 28, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, January 23, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, January 23, 2024SOU EXTENSION 2 FILED
Tuesday, January 23, 2024SOU EXTENSION 2 GRANTED
Thursday, January 25, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, July 24, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, July 24, 2024SOU EXTENSION 3 FILED
Wednesday, July 24, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, January 31, 2025TEAS STATEMENT OF USE RECEIVED
Thursday, March 20, 2025APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, March 20, 2025TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, March 20, 2025TEAS CHANGE OF OWNER ADDRESS RECEIVED
Sunday, April 13, 2025STATEMENT OF USE PROCESSING COMPLETE
Sunday, April 13, 2025CASE ASSIGNED TO INTENT TO USE PARALEGAL
Saturday, May 3, 2025ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Wednesday, July 24, 2024SOU EXTENSION 3 GRANTED
Friday, January 31, 2025USE AMENDMENT FILED
Tuesday, May 27, 2025NOTICE OF REGISTRATION CONFIRMATION EMAILED
Saturday, May 3, 2025NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Tuesday, May 27, 2025REGISTERED-PRINCIPAL REGISTER

Related Keywords

crenessity treatment pharmaceutical disorders conditions preparations congenital diseases adrenal hyperplasia orphan